Dr. Nilanju Sarmah, Head R&D and Academics, Metropolis Healthcare Limited Lung cancer is the leading cause of cancer-related ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

6 Around 80-85% of all lung cancers are non-small cell lung cancer (NSCLC) 7, and most cases of lung cancer in non-smokers ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

Content by Intermountain Health Regional Communications. Did you know that raising awareness and encouraging screening can ...

Why Many Lung Cancer Patients Who Have Never Smoked Have Worse Outcomes June 13, 2024 — The reason why targeted treatment for non-small cell lung cancer fails to work for some patients ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.